No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
Regulation of Adiposity by Para—metabobiotic Lactobacillus amylovorus CP1563 in Healthy Normal and Pre—obese Adult Individuals―A Randomized Controlled Trial―
Rent:
Rent this article for
JPY
Abstract
Objectives We aimed to evaluate the effect of daily ingestion of CP1563 on the reduction of abdominal visceral fat area(VFA)and subcutaneous fat area(SFA) and to confirm the benefits for ordinary people in their body mass indices(BMIs)from 23 or more but less than 30. Method This study was investigated in a double-blind, randomized controlled trial of 200 healthy adults with wide variations in their BMIs from 23 or greater to less than 30 and including normal to pre-obese ranges according to the criteria of the World Health Organization(WHO). Result In the CP1563 group, the abdominal VFA and total fat area(TFA) were significantly decreased, and Apolipoprotein A-I(Apo A-I)plasma concentration was also significantly increased compared with those in the placebo group during the 24-week trial period. In stratified analyses, in Cluster I which included participants with a visceral fat area of less than 100 cm2, body weight(BW), BMI, VFA, SFA and TFA were significantly decreased. Moreover, plasma concentration of Apo A-I was simultaneously increased in the CP1563 group compared with those in the placebo group. In Cluster Ⅱ included participants without metabolic syndrome(MetS)and adiposity, the BW, BMI, VFA, TFA and apolipoprotein B(Apo B)╱Apo A-I ratio were significantly decreased. In addition, Apo A︱I plasma concentration was significantly increased in the CP1563 group compared with those in the placebo group. Conclusions The fragmented para-probiotic CP1563 described in this report is effective in reducing VFA. (Trial registration:UMIN 000022842)
Full text loading...
/content/article/0386-3603/46090/1601